ALKS
Alkermes plc
Price Chart
Latest Quote
$42.80
-0.58 (-1.34%)
Current Price
| Previous Close | $43.38 |
| Open | $43.38 |
| Day High | $43.69 |
| Day Low | $42.55 |
| Volume | 1,301,146 |
Stock Information
| Shares Outstanding | 166.68M |
| Total Debt | $1.58B |
| Cash Equivalents | $511.86M |
| Revenue | $1.56B |
| Net Income | $152.72M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $7.13B |
| P/E Ratio | 47.56 |
| EPS (TTM) | $0.90 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.20B |
| Sales | $1.56B |
| Income | $152.72M |
| Book/sh | $10.52 |
| Cash/sh | $3.07 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 1.53 |
| Current Ratio | 2.27 |
| Debt/Eq | 90.30 |
Returns & Margins
| ROA | 4.72% |
| ROE | 9.36% |
| Gross Margin | 87.45% |
| Operating Margin | -0.19% |
| Profit Margin | 9.77% |
Ownership
| Insider Ownership | 1.43% |
| Institutional Ownership | 110.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 18.18 |
| PEG | 1.96 |
| P/S | 4.57 |
| P/B | 4.07 |
Analyst Data
| Recommendation | buy |
| Target Price | $45.44 |
Technical Indicators
| SMA20 | $38.93 |
| SMA50 | $35.82 |
| SMA200 | $31.50 |
| RSI | 77.31 |
| ATR | 1.5143 |
| Shares Float | 154.08M |
| Short Float | 15.23% |
| Short Ratio | 9.12 |
| Volatility | 0.33 |
| Rel Volume | 0.59 |
Performance History
| Week | +1.45% |
| Month | +21.18% |
| Quarter | +49.49% |
| 6 Months | +44.94% |
| YTD | +51.45% |
| Year | +35.70% |
| 3 Years | +47.94% |
| 5 Years | +88.80% |
| 10 Years | -6.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $42.80 | 1,312,000 |
| 2026-06-04 | $43.38 | 2,307,200 |
| 2026-06-03 | $42.76 | 2,000,500 |
| 2026-06-02 | $41.32 | 2,146,000 |
| 2026-06-01 | $42.27 | 2,406,100 |
| 2026-05-29 | $42.19 | 4,269,400 |
| 2026-05-28 | $39.94 | 2,913,200 |
| 2026-05-27 | $38.09 | 2,246,900 |
| 2026-05-26 | $37.35 | 1,122,900 |
| 2026-05-22 | $36.80 | 907,800 |
| 2026-05-21 | $36.95 | 1,692,600 |
| 2026-05-20 | $36.98 | 1,817,900 |
| 2026-05-19 | $37.00 | 2,154,200 |
| 2026-05-18 | $37.19 | 1,571,900 |
| 2026-05-15 | $37.48 | 1,315,700 |
| 2026-05-14 | $38.36 | 1,740,000 |
| 2026-05-13 | $38.91 | 3,250,700 |
| 2026-05-12 | $38.29 | 4,026,500 |
| 2026-05-11 | $35.47 | 2,323,500 |
| 2026-05-08 | $34.99 | 2,616,400 |
| 2026-05-07 | $35.40 | 2,094,200 |
| 2026-05-06 | $35.32 | 2,960,700 |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
đ° Latest News
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:27Z
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-04T15:30:06Z
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear
Simply Wall St. âĸ 2026-05-13T18:35:39Z
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires âĸ 2026-05-12T19:58:05ZSector Update: Healthcare Stocks Gain in Afternoon Trading
MT Newswires âĸ 2026-05-12T17:54:02ZAlkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says
MT Newswires âĸ 2026-05-06T16:37:39ZAlkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
Zacks âĸ 2026-05-06T16:06:00Z
Alkermes plc Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-05T20:46:28Z
Alkermes (ALKS) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-05T20:11:46Z
Alkermes Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-05T14:14:49Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $169,292,000 | $217,899,000 | $213,799,000 | $176,569,000 |
| Cost Of Revenue | $196,457,000 | $245,331,000 | $253,037,000 | $218,068,000 |
| Total Revenue | $1,475,899,000 | $1,557,632,000 | $1,663,405,000 | $1,111,795,000 |
| Operating Revenue | $1,475,899,000 | $1,557,632,000 | $1,663,405,000 | $1,111,795,000 |
| Expenses | ||||
| Interest Expense | $12,277,000 | $22,578,000 | $23,032,000 | $13,040,000 |
| Total Expenses | $1,221,943,000 | $1,136,996,000 | $1,249,283,000 | $1,117,884,000 |
| Other Income Expense | $4,467,000 | $3,242,000 | $-425,000 | $-19,628,000 |
| Other Non Operating Income Expenses | $4,467,000 | $3,242,000 | $-425,000 | $2,122,000 |
| Net Non Operating Interest Income Expense | $33,027,000 | $19,872,000 | $7,822,000 | $-5,411,000 |
| Interest Expense Non Operating | $12,277,000 | $22,578,000 | $23,032,000 | $13,040,000 |
| Operating Expense | $1,025,486,000 | $891,665,000 | $996,246,000 | $899,816,000 |
| Selling And Marketing Expense | $480,011,000 | $446,214,000 | $490,154,000 | $392,211,000 |
| General And Administrative Expense | $221,511,000 | $199,024,000 | $199,597,000 | $198,540,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $241,664,000 | $372,138,000 | $519,157,000 | $-33,152,000 |
| Net Interest Income | $33,027,000 | $19,872,000 | $7,822,000 | $-5,411,000 |
| Interest Income | $45,304,000 | $42,450,000 | $30,854,000 | $7,629,000 |
| Normalized Income | $241,664,000 | $372,138,000 | $519,157,000 | $-15,969,500 |
| Net Income From Continuing And Discontinued Operation | $241,664,000 | $367,070,000 | $355,757,000 | $-158,267,000 |
| Total Operating Income As Reported | $253,956,000 | $420,636,000 | $414,122,000 | $-6,089,000 |
| Net Income Common Stockholders | $241,664,000 | $367,070,000 | $355,757,000 | $-158,267,000 |
| Net Income | $241,664,000 | $367,070,000 | $355,757,000 | $-158,267,000 |
| Net Income Including Noncontrolling Interests | $241,664,000 | $367,070,000 | $355,757,000 | $-158,267,000 |
| Net Income Discontinuous Operations | $0 | $-5,068,000 | $-163,400,000 | $-125,115,000 |
| Net Income Continuous Operations | $241,664,000 | $372,138,000 | $519,157,000 | $-33,152,000 |
| Pretax Income | $291,450,000 | $443,750,000 | $421,519,000 | $-31,128,000 |
| Interest Income Non Operating | $45,304,000 | $42,450,000 | $30,854,000 | $7,629,000 |
| Operating Income | $253,956,000 | $420,636,000 | $414,122,000 | $-6,089,000 |
| Depreciation Amortization Depletion Income Statement | $0 | $1,101,000 | $35,689,000 | $36,363,000 |
| Depreciation And Amortization In Income Statement | $0 | $1,101,000 | $35,689,000 | $36,363,000 |
| Amortization Of Intangibles Income Statement | $0 | $1,101,000 | $35,689,000 | $36,363,000 |
| Gross Profit | $1,279,442,000 | $1,312,301,000 | $1,410,368,000 | $893,727,000 |
| Special Income Charges | - | $0 | $0 | $-21,750,000 |
| Per Share | ||||
| Diluted EPS | $1.43 | $2.17 | $2.10 | $-0.97 |
| Basic EPS | $1.47 | $2.22 | $2.14 | $-0.97 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-4,567,500 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $330,892,000 | $494,861,000 | $519,478,000 | $81,524,000 |
| Reconciled Depreciation | $27,165,000 | $28,533,000 | $74,927,000 | $77,862,000 |
| EBITDA (Bullshit earnings) | $330,892,000 | $494,861,000 | $519,478,000 | $59,774,000 |
| EBIT | $303,727,000 | $466,328,000 | $444,551,000 | $-18,088,000 |
| Diluted Average Shares | $168,743,000 | $169,198,000 | $169,730,000 | $163,742,000 |
| Basic Average Shares | $164,703,000 | $165,392,000 | $166,223,000 | $163,742,000 |
| Diluted NI Availto Com Stockholders | $241,664,000 | $367,070,000 | $355,757,000 | $-158,267,000 |
| Tax Provision | $49,786,000 | $71,612,000 | $-97,638,000 | $2,024,000 |
| Amortization | $0 | $1,101,000 | $35,689,000 | $36,363,000 |
| Research And Development | $323,964,000 | $245,326,000 | $270,806,000 | $272,702,000 |
| Selling General And Administration | $701,522,000 | $645,238,000 | $689,751,000 | $590,751,000 |
| Other Gand A | $221,511,000 | $199,024,000 | $199,597,000 | $198,540,000 |
| Total Unusual Items | - | $0 | $0 | $-21,750,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $0 | $-21,750,000 |
| Restructuring And Mergern Acquisition | - | $0 | $0 | $21,750,000 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,735,453,000 | $1,381,060,000 | $1,117,668,000 | $923,046,000 |
| Total Assets | $2,486,993,000 | $2,055,567,000 | $2,136,223,000 | $1,963,978,000 |
| Total Non Current Assets | $557,832,000 | $640,212,000 | $650,717,000 | $833,672,000 |
| Other Non Current Assets | $49,099,000 | $16,503,000 | $11,521,000 | $146,325,000 |
| Non Current Deferred Assets | $125,815,000 | $154,835,000 | $195,888,000 | $114,572,000 |
| Non Current Deferred Taxes Assets | $125,815,000 | $154,835,000 | $195,888,000 | $114,572,000 |
| Investmentin Financial Assets | $145,000 | $73,148,000 | $39,887,000 | $131,610,000 |
| Goodwill And Other Intangible Assets | $83,842,000 | $83,917,000 | $85,018,000 | $120,707,000 |
| Other Intangible Assets | $815,000 | $890,000 | $1,991,000 | $37,680,000 |
| Current Assets | $1,929,161,000 | $1,415,355,000 | $1,485,506,000 | $1,130,306,000 |
| Other Current Assets | $79,090,000 | $91,282,000 | $98,166,000 | $41,203,000 |
| Restricted Cash | $731,206,000 | $0 | - | - |
| Inventory | $196,625,000 | $182,887,000 | $186,406,000 | $181,418,000 |
| Receivables | $334,025,000 | $389,518,000 | $333,183,000 | $296,896,000 |
| Receivables Adjustments Allowances | $-400,000 | $-300,000 | $-200,000 | $-200,000 |
| Other Receivables | $65,800,000 | $74,490,000 | $103,806,000 | $80,929,000 |
| Accounts Receivable | $268,625,000 | $315,328,000 | $229,577,000 | $216,167,000 |
| Gross Accounts Receivable | $268,625,000 | $315,328,000 | $229,577,000 | $216,167,000 |
| Cash Cash Equivalents And Short Term Investments | $588,215,000 | $751,668,000 | $773,491,000 | $608,465,000 |
| Cash And Cash Equivalents | $388,570,000 | $291,146,000 | $457,469,000 | $292,473,000 |
| Assets Held For Sale Current | - | $0 | $94,260,000 | $2,324,000 |
| Allowance For Doubtful Accounts Receivable | - | - | - | $-200,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $69,999,000 | $75,538,000 | $372,185,000 | $379,435,000 |
| Long Term Debt And Capital Lease Obligation | $63,253,000 | $69,372,000 | $363,439,000 | $366,557,000 |
| Current Debt And Capital Lease Obligation | $6,746,000 | $6,166,000 | $8,746,000 | $12,878,000 |
| Long Term Debt | - | - | $287,730,000 | $290,270,000 |
| Current Debt | - | - | $3,000,000 | $3,000,000 |
| Other Current Borrowings | - | - | $3,000,000 | $3,000,000 |
| Net Debt | - | - | - | $797,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $667,698,000 | $590,590,000 | $933,537,000 | $920,225,000 |
| Total Non Current Liabilities Net Minority Interest | $124,261,000 | $125,391,000 | $413,317,000 | $422,483,000 |
| Other Non Current Liabilities | $61,008,000 | $56,019,000 | $49,878,000 | $42,384,000 |
| Current Liabilities | $543,437,000 | $465,199,000 | $520,220,000 | $497,742,000 |
| Current Deferred Liabilities | $0 | $1,249,000 | $2,730,000 | $6,816,000 |
| Payables And Accrued Expenses | $454,241,000 | $386,824,000 | $421,095,000 | $393,119,000 |
| Payables | $107,950,000 | $45,630,000 | $65,649,000 | $32,843,000 |
| Accounts Payable | $107,950,000 | $45,630,000 | $65,649,000 | $32,843,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $13,542,000 |
| Other Current Liabilities | - | - | $4,542,000 | $5,844,000 |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $1,819,295,000 | $1,464,977,000 | $1,202,686,000 | $1,043,753,000 |
| Total Equity Gross Minority Interest | $1,819,295,000 | $1,464,977,000 | $1,202,686,000 | $1,043,753,000 |
| Stockholders Equity | $1,819,295,000 | $1,464,977,000 | $1,202,686,000 | $1,043,753,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,100,000 | $-1,967,000 | $-3,110,000 | $-10,889,000 |
| Other Equity Adjustments | $-2,100,000 | $-1,967,000 | $-3,110,000 | $-10,889,000 |
| Retained Earnings | $-734,794,000 | $-976,458,000 | $-1,343,528,000 | $-1,699,285,000 |
| Other | ||||
| Treasury Shares Number | $15,404,138 | $14,493,791 | $5,589,218 | $4,574,184 |
| Ordinary Shares Number | $165,607,028 | $162,176,994 | $166,979,833 | $164,377,009 |
| Share Issued | $181,011,166 | $176,670,785 | $172,569,051 | $168,951,193 |
| Tangible Book Value | $1,735,453,000 | $1,381,060,000 | $1,117,668,000 | $923,046,000 |
| Invested Capital | $1,819,295,000 | $1,464,977,000 | $1,493,416,000 | $1,337,023,000 |
| Working Capital | $1,385,724,000 | $950,156,000 | $965,286,000 | $632,564,000 |
| Capital Lease Obligations | $69,999,000 | $75,538,000 | $81,455,000 | $86,165,000 |
| Total Capitalization | $1,819,295,000 | $1,464,977,000 | $1,490,416,000 | $1,334,023,000 |
| Treasury Stock | $450,287,000 | $419,255,000 | $189,336,000 | $160,862,000 |
| Additional Paid In Capital | $3,004,666,000 | $2,860,890,000 | $2,736,934,000 | $2,913,099,000 |
| Capital Stock | $1,810,000 | $1,767,000 | $1,726,000 | $1,690,000 |
| Common Stock | $1,810,000 | $1,767,000 | $1,726,000 | $1,690,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $63,253,000 | $69,372,000 | $75,709,000 | $76,287,000 |
| Current Deferred Revenue | $0 | $1,249,000 | $2,730,000 | $6,816,000 |
| Current Capital Lease Obligation | $6,746,000 | $6,166,000 | $5,746,000 | $9,878,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $82,450,000 | $70,960,000 | $83,107,000 | $79,085,000 |
| Current Accrued Expenses | $346,291,000 | $341,194,000 | $355,446,000 | $360,276,000 |
| Investments And Advances | $145,000 | $73,148,000 | $39,887,000 | $131,610,000 |
| Held To Maturity Securities | $145,000 | $145,000 | $39,887,000 | $131,610,000 |
| Goodwill | $83,027,000 | $83,027,000 | $83,027,000 | $83,027,000 |
| Net PPE | $298,931,000 | $311,809,000 | $318,403,000 | $320,458,000 |
| Accumulated Depreciation | $-267,010,000 | $-253,012,000 | $-230,161,000 | $-214,761,000 |
| Gross PPE | $565,941,000 | $564,821,000 | $548,564,000 | $535,219,000 |
| Leases | $42,535,000 | $42,416,000 | $39,893,000 | $31,642,000 |
| Construction In Progress | $38,795,000 | $58,391,000 | $45,791,000 | $78,017,000 |
| Other Properties | $77,209,000 | $84,245,000 | $91,460,000 | $97,539,000 |
| Machinery Furniture Equipment | $255,773,000 | $244,113,000 | $237,728,000 | $222,408,000 |
| Buildings And Improvements | $150,672,000 | $134,699,000 | $132,735,000 | $104,666,000 |
| Land And Improvements | $957,000 | $957,000 | $957,000 | $947,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $37,740,000 | $30,877,000 | $46,147,000 | $44,126,000 |
| Work In Process | $90,498,000 | $79,871,000 | $68,843,000 | $76,228,000 |
| Raw Materials | $68,387,000 | $72,139,000 | $71,416,000 | $61,064,000 |
| Other Short Term Investments | $199,645,000 | $460,522,000 | $316,022,000 | $315,992,000 |
| Available For Sale Securities | - | $73,003,000 | - | - |
| Non Current Deferred Revenue | - | - | - | - |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $480,334,000 | $405,640,000 | $353,305,000 | $-17,211,000 |
| Operating Activities | ||||
| Operating Cash Flow | $520,754,000 | $439,124,000 | $401,353,000 | $21,044,000 |
| Cash Flow From Continuing Operating Activities | $520,754,000 | $439,124,000 | $401,353,000 | $21,044,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-40,420,000 | $-33,484,000 | $-48,048,000 | $-38,255,000 |
| Investing Cash Flow | $295,497,000 | $-111,308,000 | $53,357,000 | $-64,541,000 |
| Cash Flow From Continuing Investing Activities | $295,497,000 | $-111,308,000 | $53,357,000 | $-64,541,000 |
| Net Other Investing Changes | - | - | - | $1,273,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-200,282,000 | $0 | $0 |
| Financing Cash Flow | $12,379,000 | $-494,139,000 | $-289,714,000 | $-1,574,000 |
| Cash Flow From Continuing Financing Activities | $12,379,000 | $-494,139,000 | $-289,714,000 | $-1,574,000 |
| Net Other Financing Charges | $-31,032,000 | $-29,637,000 | $-303,474,000 | $-18,204,000 |
| Net Common Stock Issuance | $0 | $-200,282,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-291,792,000 | $-3,000,000 | $-3,000,000 |
| Interest Paid Supplemental Data | $0 | $23,010,000 | $22,748,000 | $13,563,000 |
| Income Tax Paid Supplemental Data | $5,237,000 | $2,592,000 | $44,243,000 | $20,749,000 |
| End Cash Position | $1,119,776,000 | $291,146,000 | $457,469,000 | $292,473,000 |
| Beginning Cash Position | $291,146,000 | $457,469,000 | $292,473,000 | $337,544,000 |
| Changes In Cash | $828,630,000 | $-166,323,000 | $164,996,000 | $-45,071,000 |
| Proceeds From Stock Option Exercised | $43,411,000 | $27,572,000 | $16,760,000 | $19,630,000 |
| Common Stock Payments | $0 | $-200,282,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $-291,792,000 | $-3,000,000 | $-3,000,000 |
| Net Long Term Debt Issuance | $0 | $-291,792,000 | $-3,000,000 | $-3,000,000 |
| Long Term Debt Payments | $0 | $-291,792,000 | $-3,000,000 | $-3,000,000 |
| Net Investment Purchase And Sale | $333,123,000 | $-176,261,000 | $101,051,000 | $-28,044,000 |
| Sale Of Investment | $697,492,000 | $310,286,000 | $355,522,000 | $281,627,000 |
| Purchase Of Investment | $-364,369,000 | $-486,547,000 | $-254,471,000 | $-309,671,000 |
| Net Business Purchase And Sale | $1,708,000 | $97,976,000 | $0 | $1,758,000 |
| Sale Of Business | $1,708,000 | $97,976,000 | $0 | $1,758,000 |
| Net PPE Purchase And Sale | $-39,334,000 | $-33,023,000 | $-47,694,000 | $-38,255,000 |
| Sale Of PPE | $1,086,000 | $461,000 | $354,000 | $0 |
| Purchase Of PPE | $-40,420,000 | $-33,484,000 | $-48,048,000 | $-38,255,000 |
| Change In Working Capital | $119,124,000 | $-98,150,000 | $-36,663,000 | $12,709,000 |
| Change In Other Working Capital | $-1,249,000 | $-3,525,000 | $-5,926,000 | $-7,129,000 |
| Change In Other Current Liabilities | $-5,027,000 | $-1,693,000 | $-6,813,000 | $-20,499,000 |
| Change In Other Current Assets | $7,549,000 | $7,215,000 | $15,387,000 | $16,569,000 |
| Change In Payables And Accrued Expense | $75,567,000 | $-49,156,000 | $34,535,000 | $30,433,000 |
| Change In Accrued Expense | $-25,326,000 | $8,811,000 | $11,526,000 | $14,899,000 |
| Change In Payable | $100,893,000 | $-57,967,000 | $23,009,000 | $15,534,000 |
| Change In Account Payable | $100,893,000 | $-57,967,000 | $23,009,000 | $15,534,000 |
| Change In Prepaid Assets | $852,000 | $2,254,000 | $-34,847,000 | $-5,328,000 |
| Change In Inventory | $-14,061,000 | $3,091,000 | $-2,712,000 | $-31,021,000 |
| Change In Receivables | $55,493,000 | $-56,336,000 | $-36,287,000 | $29,684,000 |
| Changes In Account Receivables | $50,503,000 | $-52,052,000 | $-44,510,000 | $25,250,000 |
| Other Non Cash Items | $5,311,000 | $4,512,000 | $6,329,000 | $27,281,000 |
| Stock Based Compensation | $98,716,000 | $96,637,000 | $100,905,000 | $94,254,000 |
| Deferred Tax | $28,774,000 | $40,522,000 | $-99,902,000 | $-32,795,000 |
| Deferred Income Tax | $28,774,000 | $40,522,000 | $-99,902,000 | $-32,795,000 |
| Depreciation Amortization Depletion | $27,165,000 | $28,533,000 | $74,927,000 | $77,862,000 |
| Depreciation And Amortization | $27,165,000 | $28,533,000 | $74,927,000 | $77,862,000 |
| Net Income From Continuing Operations | $241,664,000 | $367,070,000 | $355,757,000 | $-158,267,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
| Purchase Of Business | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-05-30